Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advances in the assessment of minimal residual disease in mantle cell lymphoma

24 Sept 2020

Abstract excerpt

The clinical impact of minimal residual disease detection at early time points or during follow-ups has been shown to accurately predict relapses among patients with lymphomas, mainly in follicular and diffuse large B cell lymphoma. The field of minimal residual disease testing in mantle cell lymphoma is still evolving but has great impact in determining the prognosis. Flow cytometry and polymerase chain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lymphoma Diagnosis and Treatment
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32972438
DOI: 10.1186/s13045-020-00961-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advances in the assessment of minimal residual disease in mantle cell lymphomaPMID 32972438Read ↗

Minimal Residual Disease in Oncology: From Cure to Longitudinal Patient ManagementSemantic proximity Read ↗

Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature ReviewSemantic proximity Read ↗

Biological and clinical determinants shaping heterogeneity in mantle cell lymphomaSemantic proximity Read ↗

Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markersSemantic proximity Read ↗

Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.Semantic proximity Read ↗

Mantle cell lymphoma pathology update in the 2016 WHO classificationSemantic proximity Read ↗

Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological MalignanciesSemantic proximity Read ↗

Minimal Residual Disease Detection in Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow‐up Samples From Four Prospective Trials of the European MCL NetworkSemantic proximity Read ↗

Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium WorkshopSemantic proximity Read ↗

Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.Semantic proximity Read ↗

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future PerspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.